Democritus University of Thrace (DUTH)
Μελέτη κυτταρικών θεραπειών για χρόνιες πνευμονικές νόσους
Abstract
dc:descriptionBackground: Idiopathic Pulmonary Fibrosis (IPF) is a lethal, destructive form of lung scarring disease of unknown pathogenesis. The use of cell therapies has recently emerged as an alternative option or even salvage treatment for end-stage lung disease. Mesenchymal Stem Cells represent a cell therapy option with many advantages. They can be easily harvested from many tissues and expanded in vitro with slight modifications. Their capacity for differentiation in different cell lines has been demonstrated. Numerous experimental studies support the concept of anti-inflammatory, immunomodulatory and potential anti-fibrotic properties of MSC. Importantly, MSCs are considered to be “immune privileged”.Aim: Our study group launched a phase Ib study aiming to explore the safety profile of the endobronchial infusion of autologous Adipose Derived Stem Cells – Stromal Vascular Fraction in a small cohort of patients with IPF (n=14) of mild-to-moderate disease severity. Our secondary endpoint was to assess efficacy based on pulmonary function tests, exercise capacity and indices of quality of life. Results: Results of this study demonstrated an acceptable safety and tolerability profile of endobronchial infusion of ADSCs-SVF during the entire study period (60 months), as indicated by absence of acute or chronic adverse events. Our patients experienced significant reductions in both %FVC and %DLCO at 24 and 18 months, respectively, following first endobronchial infusion; yet, declines in both were equal to 6% and thus did not exceed the clinically meaningful threshold of 10% and 15% respectively. Disease progression occurred 26 months following first administration of stem cells and median survival was 32 months. Importantly all our patients were alive 24 months and two patients are still alive 5 years after study initiation.Conclusions: To conclude, our study reports an acceptable longitudinal safety profile. Stem cell therapy failed to demonstrate improvement in lung function, however our study was underpowered for that endpoint and results have to be addressed with caution. Larger randomized placebo-controlled clinical trials are needed to assess the efficacy of stem cell treatment in patients with IPF.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ntolios, Paschalis
- Ντόλιος, Πασχάλης
Subjects
dc:subject × 6Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44463